Earnings Beat: Jupiter Life Line Hospitals Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jupiter Life Line Hospitals Limited (NSE:JLHL) shareholders are probably feeling a little disappointed, since its shares fell 2.1% to ₹322 in the week after its latest first-quarter results. Revenues of ₹4.1b fell slightly short of expectations, but earnings were a definite bright spot, with statutory per-share profits of ₹5.72 an impressive 257% ahead of estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
After the latest results, the six analysts covering Jupiter Life Line Hospitals are now predicting revenues of ₹18.1b in 2027. If met, this would reflect a solid 16% improvement in revenue compared to the last 12 months. Per-share earnings are expected to step up 13% to ₹6.47. Before this earnings report, the analysts had been forecasting revenues of ₹18.2b and earnings per share (EPS) of ₹6.60 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
Check out our latest analysis for Jupiter Life Line Hospitals
The consensus price target rose 6.2% to ₹339despite there being no meaningful change to earnings estimates. It could be that the analystsare reflecting the predictability of Jupiter Life Line Hospitals' earnings by assigning a price premium. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Jupiter Life Line Hospitals, with the most bullish analyst valuing it at ₹410 and the most bearish at ₹310 per share. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Jupiter Life Line Hospitals' rate of growth is expected to accelerate meaningfully, with the forecast 22% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 16% p.a. over the past three years. Compare this with other companies in the same industry, which are forecast to grow their revenue 18% annually. Jupiter Life Line Hospitals is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.
The Bottom Line
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
With that in mind, we wouldn't be too quick to come to a conclusion on Jupiter Life Line Hospitals. Long-term earnings power is much more important than next year's profits. We have forecasts for Jupiter Life Line Hospitals going out to 2029, and you can see them free on our platform here.
It might also be worth considering whether Jupiter Life Line Hospitals' debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.